


Participant Flow



Baseline Characteristics

Age	Sex	How long on Methotrexate (Years)	Drug Satisfaction (on analogue scale 1 worst to 10 best)
72	F	10	10
45	M	2	1
59	F	4	7
53	M	0.43	9
56	F	1	7
72	M	10	8
66	M	1.5	7
67	F	2	6
41	F	1.08	5
35	M	5	5
67	M	4	8
47	M	9	2
59	M	1.5	9
76	M	10	10
51	F	1	5
59	F	3	8
80	F	10	10
65	F	13	7
67	M	7	8
51	M	0.5	10
67	F	8	10
59	F	6	7
76	M	1	7
75	F	15	10
41	F	2.6	7
46	F	1	7
49	M	11	10
52	F	2	8
63	F	0.65	3
73	F	0.08	8
53	F	0.08	4
61	F	2	10
70	M	1	2
59	M	3.5	5
86	M	30	10
56	F	13	7
61	F	6	8
43	F	14	8
33	M	0.75	9
44	M	5	4

52	F	0.25	10
41	F	7	10
64	F	4	10
62	F	8	8
45	F	20	9
58	F	0.65	3
67	F	1	9
25	F	1	7
59	F	2	8
37	F	0.1	7
61	F	1.5	9
59	F	2	7
82	F	0.4	10
45	M	0.4	7
72	F	3	10
87	F	14	10
50	F	5	5
58	F	5	6
82	F	4	10
64	F	5	10
80	M	4	9
52	F	10	10
67	F	2	7
63	M	10	10
64	F	8	10
74	M	4	8
77	F	0.5	9
83	F	8	9
64	F	4	5
64	F	0.5	3
65	F	7.5	6
70	F	2	9
65	F	10	10

Outcome Measures Results

	Received methotrexate education booklet at baseline	
	No (n=15)	Yes (n=21)
Male sex	53%	33%
Age, years (IQR)	61 (55-65)	59 (47-71)
Duration Methotrexate, years (IQR)	5.4 (1.8,-7.5)	4.0 (1.5-8.0)
Missed doses between visits ¹	0 (0-5)	2 (0-7)
Dose of Methotrexate, mg/week ¹	15 (10-20)	17.5 (10-20)
Subcutaneous administration	40%	25%
Dose Increase during follow-up	7%	10%
Baseline C-Reactive Protein ¹	14 (9-22)	12 (5-29)
Baseline Erythrocyte Sedimentation Rate ¹	14 (8-22)	12 (6-27)
Baseline Satisfaction	8 (8-10)	8 (7-10)
Baseline Methotrexate Knowledge Test ¹	9 (6-13)	13 (12-16)
Baseline Methotrexate_Glu3, fmol/10 ¹² RBC ¹	13512 (7062-21912)	12770 (10589-19637)
Satisfaction Change ¹	0 (0-1.5)	0 (-1-0)
Questionnaire Change ¹	0 (-5.5-4.5)	1 (-4-4)
MTX_G3_Change ¹	3124 [-345-12807]	2152 [-282-4485]
Forgotten Doses ¹	0 (0-0)	0 (0-0)
Doses deliberately not taken ¹	1 (1-1)	1 (1-2)

Adverse Events

There were no adverse events.